MicroStrategy, led by co-founder Michael Saylor, has acquired an additional 1,036 Bitcoin, increasing its already substantial cryptocurrency reserves. As of November 8, the company held 850,364 BTC and $4.9 billion in U.S. dollar assets. This purchase highlights MicroStrategy's ongoing commitment to Bitcoin as a primary reserve asset, a strategy strongly advocated by Saylor. Alongside the Bitcoin acquisition, the company also repurchased $188 million of its own stock, showing continued financial maneuvering to support its crypto-focused strategy.
Michael Saylor's recent Bitcoin acquisition and MicroStrategy's large BTC holdings provide context for cryptocurrency market activity. For readers following digital assets, here is Pluang's market snapshot as of Nov 10, 2026 17:41 WIB: Of 50 major cryptocurrencies priced on Pluang, 33 rose and 16 fell today. Notable gainers include THETA at Rp2,569 (+3.05%), SAND at Rp782 (+3.02%), and FIL at Rp13,954 (+2.94%), with strong buy order activity on these tokens.
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
ESET Research uncovered a sophisticated cyberespionage tool named Cereal, used by the Russia-aligned Turla group to spy on emails within Microsoft Exchange servers of governmental organizations in Kazakhstan and Romania. The tool stealthily collects ...
The global paracetamol market is projected to grow from $12.05 billion in 2026 to $15.39 billion by 2032, with a CAGR of 4.12%. Growth is driven by increasing demand for pain and fever management, expanded access to over-the-counter medicines, and in...
Registration is now open for Brand Licensing Expo 2027, scheduled for May 25-27 at Mandalay Bay, Las Vegas. The event, rebranded from Licensing Expo, features over 265 confirmed exhibitors including major brands like Amazon MGM Studios, Coca-Cola, an...
Trogenix, a clinical-stage precision oncology company, has appointed John Young as Chair and Josh Murray as Non-Executive Director to support its global strategy, commercial growth, and US expansion. John Young brings over 35 years of pharmaceutical ...
